BCRX vs. HALO, RGEN, MDGL, IONS, ALKS, LGND, FOLD, CLDX, MNKD, and INVA
Should you be buying BioCryst Pharmaceuticals stock or one of its competitors? The main competitors of BioCryst Pharmaceuticals include Halozyme Therapeutics (HALO), Repligen (RGEN), Madrigal Pharmaceuticals (MDGL), Ionis Pharmaceuticals (IONS), Alkermes (ALKS), Ligand Pharmaceuticals (LGND), Amicus Therapeutics (FOLD), Celldex Therapeutics (CLDX), MannKind (MNKD), and Innoviva (INVA). These companies are all part of the "biotechnology" industry.
BioCryst Pharmaceuticals vs. Its Competitors
BioCryst Pharmaceuticals (NASDAQ:BCRX) and Halozyme Therapeutics (NASDAQ:HALO) are both mid-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, media sentiment, profitability, analyst recommendations, risk, valuation, dividends and community ranking.
85.9% of BioCryst Pharmaceuticals shares are held by institutional investors. Comparatively, 97.8% of Halozyme Therapeutics shares are held by institutional investors. 4.8% of BioCryst Pharmaceuticals shares are held by company insiders. Comparatively, 2.4% of Halozyme Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
BioCryst Pharmaceuticals has a beta of 1.11, indicating that its share price is 11% more volatile than the S&P 500. Comparatively, Halozyme Therapeutics has a beta of 1.19, indicating that its share price is 19% more volatile than the S&P 500.
Halozyme Therapeutics has a net margin of 43.74% compared to BioCryst Pharmaceuticals' net margin of -30.01%. Halozyme Therapeutics' return on equity of 157.78% beat BioCryst Pharmaceuticals' return on equity.
Halozyme Therapeutics received 31 more outperform votes than BioCryst Pharmaceuticals when rated by MarketBeat users. Likewise, 69.10% of users gave Halozyme Therapeutics an outperform vote while only 67.16% of users gave BioCryst Pharmaceuticals an outperform vote.
Halozyme Therapeutics has higher revenue and earnings than BioCryst Pharmaceuticals. BioCryst Pharmaceuticals is trading at a lower price-to-earnings ratio than Halozyme Therapeutics, indicating that it is currently the more affordable of the two stocks.
BioCryst Pharmaceuticals currently has a consensus price target of $16.56, indicating a potential upside of 56.04%. Halozyme Therapeutics has a consensus price target of $61.90, indicating a potential upside of 14.95%. Given BioCryst Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe BioCryst Pharmaceuticals is more favorable than Halozyme Therapeutics.
In the previous week, Halozyme Therapeutics had 1 more articles in the media than BioCryst Pharmaceuticals. MarketBeat recorded 8 mentions for Halozyme Therapeutics and 7 mentions for BioCryst Pharmaceuticals. Halozyme Therapeutics' average media sentiment score of 1.39 beat BioCryst Pharmaceuticals' score of 1.06 indicating that Halozyme Therapeutics is being referred to more favorably in the news media.
Summary
Halozyme Therapeutics beats BioCryst Pharmaceuticals on 14 of the 18 factors compared between the two stocks.
Get BioCryst Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for BCRX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding BCRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
BioCryst Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:BCRX) was last updated on 6/12/2025 by MarketBeat.com Staff
